New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL). A pair of studies examining the role of venetoclax ...

1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

Tailoring the duration of venetoclax (Venclexta; AbbVie, Genentech) treatment may optimize the therapeutic efficacy of the treatment in patients with newly diagnosed acute myeloid leukemia (AML ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma. Fixed duration ...

Venetoclax (Brand name: Venclexta) is a targeted treatment for chronic lymphocytic leukemia (CLL). It targets a specific protein called BCL-2 in cancer cells that helps them stay alive. Doctors ...

Introduction: Progressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN ...

Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib and venetoclax with or without obinutuzumab within its marketing authorisation for previously untreated chronic ...

Japan 10 Year Government Bond-0.0130 1.1964% ...

The medicines and health conditions are: venetoclax (brand name Venclexta) in combination with azacitidine or cytarabine for a type of blood cancer called acute myeloid leukaemia azacitidine to be ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.